Hemics successfully closes new financing round and obtains CE marking
9 January 2015, Eindhoven, The Netherlands – Hemics announces today that it received CE marking required for commercial sales of its medical device, the HandScan, and closed a new investment round, welcoming new investor DFZ Participaties. Existing investors Thuja Capital, Point One Innovation Fund, and the Brabant Development Agency (BOM) also participated. The investment will enable Hemics to further develop, clinically test and market the HandScan, an optical imaging device to monitor joint inflammation in hands and wrists of Rheumatoid Arthritis (RA) patients.
Ben Dijk, Investment Director at DFZ Participaties: “We are excited to be part of this venture. We found in Hemics a unique product and a first class management. We expect that Hemics’ technology will allow for more frequent monitoring of patients, in the long run reducing joint damage, functional loss and discomfort for RA patients, at lower total health care cost.” Ben Dijk will join the Board of Directors of Hemics.